阿替普酶与瑞替普酶用于中国急性心肌梗死患者的安全性分析

Safety analysis of ateplase and reteplase in Chinese patients with acute myocardial infarction

目的比较阿替普酶与瑞替普酶用于中国急性心肌梗死患者的安全性。方法计算机检索Cochrane图书馆、PubMed、EmBase、中国知网、中国生物医学文献、维普和万方等数据库,并手工检索关于阿替普酶和瑞替普酶治疗中国急性心肌梗死患者疗效的文献,用RevMan 5.3软件对病死率、心律失常发生率、心力衰竭发生率和出血发生率进行Meta分析。结果在进行文献筛查后,纳入文献34篇,共包含3140例次研究对象。Meta分析结果显示,阿替普酶和瑞替普酶治疗中国急性心肌梗死患者的病死率分别为6.07%(72例/1186例)和4.62%(52例/1124例),心律失常发生率分别为28.48%(192例/674例)和26.19%(181例/691例),心力衰竭发生率分别为9.36%(82例/876例)和7.27%(65例/894例),出血发生率分别为17.85%(193例/1081例)和16.53%(169例/1022例),差异均无统计学意义(均P>0.05)。结论阿替普酶与瑞替普酶用于治疗中国急性心肌梗死患者的安全性相似。

Objective To comparing the safety of alteplase and reteplase in patients with acute myocardial infarction in China.Methods Cochrane library,PubMed,EmBase,CNKI,CBM,Weipu Data,Wanfang Data and other databases were searched,and the related literature about the efficacy of alteplase and reteplase in the treatment of acute myocardial infarction in China was also searched.The mortality,arrhythmia,heart failure and hemorrhage were analyzed by Revman 5.3.Results After the literature screening,34 articles,3140 cases were included.The mortality rates of alteplase and reteplase were 6.07%(72 cases/1186 cases)and 4.62%(52 cases/1124 cases),the incidences of arrhythmia were 28.48%(192 cases/674 cases)and 26.19%(181 cases/691 cases),the rates of heart failures were 9.36%(82 cases/876 cases)and 7.27%(65 cases/894 cases),the rates of hemorrhage were 17.85%(193 cases/1081 cases)and 16.53%(169 cases/1022 cases).There were no significant differences in patients with acute myocardial infarction after treatment with alteplase and reteplase(all P>0.05).Conclusion The safety of reteplase in the treatment of acute myocardial infarction in China is the same as that of alteplase.